clinical trial · NCT07483489
A Phase 2 Study of HW091077 in Participants With Refractory Chronic Cough Or Unexplained Chronic Cough (RCC/UCC).
Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.·phase2·not yet recruiting·n = 180
Refractory Chronic CoughHW091077HW091077Matching placebo to HW091077
brief summary
This is a randomized, multicenter, double-blind, placebo-controlled, parallel-designed phase 2 clinical trial to evaluate the efficacy, safety and pharmacokinetic (PK) characteristics of HW091077 in Chinese adult subjects with refractory chronic cough or unexplained chronic cough (RCC/UCC).
started
May 1, 2026
primary completion
Aug 30, 2028
completion
Aug 30, 2028
last updated
Mar 19, 2026
official title
A Randomized，Double-Blind, Multicenter，Placebo-Controlled, Parallel-Arm, Phase 2 Study to Evaluate the Efficacy and Safety of HW091077 in Participants With Refractory Chronic Cough or Unexplained Chronic Cough (RCC/UCC).
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol